Table 1.
Characteristics of eligible studies.
| Study | Year | Phase | Population | Platinum/ICI group | pCR | AT group | pCR |
|---|---|---|---|---|---|---|---|
| BrignTNess (13) | 2018 | 3 | stage II–III TNBC | PCb-AC | 57.50% | P-AC | 31.01% |
| CALGB (14) | 2014 | 2 | stage II–III TNBC | PCb-ddAC | 48.65% | P-ddAC | 29.25% |
| GEICAM/2006-03 (15) | 2012 | 2 | TNBC | EC-DCb | 29.79% | EC-D | 34.78% |
| GeparOcto (16) | 2019 | 3 | T1c-T4a-d TNBC and HER2+ BC | PMCb | 51.72% | ddEPC | 48.50% |
| GeparNuevo (17) | 2019 | 2 | T2-T4a-d TNBC | Durva(nab-P-ddEC) | 53.40% | nab-P-ddEC | 44.20% |
| I-SPY2 (18) | 2020 | 2 | high-risk stage II–III BC | PembroP-AC | 67.80% | P-AC | 21.35% |
| IMpassion031 (19) | 2020 | 3 | stage II–III TNBC | Atezo(nab-P-AC) | 57.60% | nab-P-AC | 41.10% |
pCR, pathological complete response; A, doxorubicin; C, cyclophosphamide; Cb, carboplatin; D, docetaxel; E, epirubin; M, non-pegylated liposomal doxorubicin; P, paclitaxel; nab-P, nab-paclitaxel; dd, dose-dense; Durva, durvalumab; Pembro,pembrolizumab; Atezo, atezolizumab.